KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions for drug delivery in home and ambulatory care settings. Its Freedom Syringe Infusion System includes Freedom60 and FreedomEDGE syringe infusion drivers, Precision Flow Rate Tubing, and HigH-Flo Subcutaneous Safety Needle Sets.
Company updates commonly cover quarterly results, revenue guidance, cash flow trends, FDA 510(k) clearances, EU MDR certification, and label expansions, including FreedomEDGE use for RYSTIGGO delivery. News also addresses pharma services and clinical-trial collaborations with biopharmaceutical companies, customization of the Freedom System across drug categories, and governance or leadership succession matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
KORU Medical Systems (NASDAQ: KRMD) has announced that it will report its first quarter 2023 financial results on May 4, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide updates on corporate developments. The call can be accessed by dialing (800)-734-8507 for U.S. participants, or (212)-231-2925 for international calls, using conference ID: 22026692. A live and archived webcast will also be available on the company’s website. KORU Medical focuses on innovative subcutaneous drug delivery systems designed to enhance patient quality of life, with products like the FREEDOM Syringe Infusion System.
KORU Medical Systems, Inc. (NASDAQ: KRMD) reported strong financial results for Q4 and the full year 2022, achieving a 13% increase in net revenue for Q4 to $7.3 million and 19% growth for the year, totaling $27.9 million. The company saw significant growth in its Novel Therapies business, with revenues skyrocketing 259.9% in Q4, thanks to new collaborations. Although the gross profit increased by 6.4%, it dropped as a percentage of revenue to 55.5% due to rising manufacturing costs. The company anticipates 2023 revenue between $32.5 million and $33.5 million, representing a 17-20% growth.
KORU Medical Systems (NASDAQ: KRMD) announced it will report its fourth quarter and full year 2022 financial results on March 8, 2023, at 4:30 p.m. ET. A conference call and webcast will follow to discuss the results and provide a corporate update. The company's product line includes the FREEDOM Syringe Infusion System, which supports patient home care with innovative drug delivery solutions. Investors can access the call by dialing the provided numbers for the U.S., Canada, and international callers, or via the archived webcast on the company’s website.
KORU Medical Systems, Inc. (NASDAQ: KRMD) has announced a development agreement with a pharmaceutical company to enhance its Freedom Infusion System for subcutaneous immunoglobulin therapy using prefilled syringes. This adaptation aims to facilitate home drug delivery for patients, as prefilled syringes are preferred for their ease of use. The Freedom Infusion System is the only approved system for this application. While the financial terms of the agreement remain undisclosed, the partnership is seen as a significant step towards expanding the number of FDA-approved therapies available for patients globally.